

JAN 04 2008

Merchant & Gould
An Intellectual Property Law FirmMerchant & Gould P.C.
3200 IDS Center
80 South Eighth Street
Minneapolis, MN 55402-2215

A Professional Corporation

Fax Transmission | January 4, 2007

TO:

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450	FROM: Gregory A. Sebald OUR REF: 09997.0136USWO TELEPHONE: 612.332.5300
--	---


Total pages, including cover letter: 7

PTO FAX NUMBER 1-571-273-8300

If you do NOT receive all of the pages, please telephone us at 612.332.5300, or fax us at 612.332.9081.

Title of Document Transmitted:	<u>Amendment</u>
Applicant:	<u>BARVAIS et al.</u>
Serial No.:	<u>10/584,182</u>
Filed:	<u>August 3, 2007</u>
Group Art Unit:	<u>3763</u>
Our Ref. No.	<u>09997.0136USWO</u>
Confirmation No.:	<u>1255</u>

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Gregory A. Sebald
Reg. No.: 33,280

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Karen R. Nejedly
Signature
Date

GEN033.DOT

**RECEIVED
CENTRAL FAX CENTER****JAN 04 2008**

S/N 10/584,182

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	BARVAIS et al.	Examiner:	Unknown
Serial No.:	10/584,182	Group Art Unit:	3763
Filed:	August 3, 2007	Docket No.:	09997.0136USWO
Title:	COMPUTER-CONTROLLED INTRAVENOUS DRUG DELIVERY SYSTEM		

CERTIFICATE UNDER 37 CFR 1.6(d): The undersigned hereby certifies that this correspondence is being transmitted via facsimile to the United States Patent and Trademark Office on January 4, 2008.

By: 
Name: Karen R. Nejedly

AMENDMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed December 4, 2007, please amend the above-referenced application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 6 of this paper.